Objective: This research is to evaluate the effectiveness of the FEC regimen as adjuvant therapy for breast cancer patients with involved lymph nodes.Patients and methods: 52 patients diagnosed breast cancer with involved axillary nodes. They were received chemotherapy with FEC regimen (5Flourouracin 600mg/m2 Cyclophosphamide 500mg/m2. Epirubicin 100mg/m2). Results: The overall survival (OS) at 3 years was 82.5 percent, the medium survival was 34.1 months. The disease free survival (DFS) of stage II was 95.7 percent; stage IlIA was 62.5 percent, stage IIIB was 37.5 percent (p = O,007). The DFS in group with Her-2/neu (+) was 80.8 percent and Her-2/neu (-) was 87.5 percent (p = 0,628).The DFS in group with or or = 4 nodes was 66.6 percent (p =0.068). The DFS in group with ER (+) was 87.5 percent, ER (-) was 79.9 percent (p = 0.810). Conclusion: The effectiveness of adjuvant therapy of FEC on 52 patients diagnosed breast cancer with involved axillary lymph nodes are acceptability.
- Đăng nhập để gửi ý kiến